Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men

Stephen Taylor; H Reynolds; CA Sabin; Susan Drake; David White; DJ Back; Deenan Pillay

Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men

Stephen Taylor, H Reynolds, CA Sabin, Susan Drake, David White, DJ Back, Deenan Pillay

Immunology and Immunotherapy

Research output: Contribution to journal › Article

34 Citations (Scopus)

Abstract

Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor, licensed for the treatment of HIV-1. Data on sanctuary site penetration are limited. Therefore, we measured efavirenz concentrations in the blood and semen of 19 HIV-1-positive men and found concentrations in seminal plasma averaged 10% of those in blood plasma. Furthermore, seminal plasma viral loads were suppressed by 24 weeks of therapy in all patients. These data suggest that efavirenz-containing regimens have antiviral activity within the male genital tract.

Original language	English
Pages (from-to)	2051-2053
Number of pages	3
Journal	Aids
Volume	15
Issue number	15
Publication status	Published - 1 Oct 2001

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{1ba7c1df99fd49b8980cbc7b68894542,

title = "Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men",

abstract = "Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor, licensed for the treatment of HIV-1. Data on sanctuary site penetration are limited. Therefore, we measured efavirenz concentrations in the blood and semen of 19 HIV-1-positive men and found concentrations in seminal plasma averaged 10% of those in blood plasma. Furthermore, seminal plasma viral loads were suppressed by 24 weeks of therapy in all patients. These data suggest that efavirenz-containing regimens have antiviral activity within the male genital tract.",

author = "Stephen Taylor and H Reynolds and CA Sabin and Susan Drake and David White and DJ Back and Deenan Pillay",

year = "2001",

month = oct,

day = "1",

language = "English",

volume = "15",

pages = "2051--2053",

journal = "Aids",

publisher = "Lippincott Williams and Wilkins",

number = "15",

}

TY - JOUR

T1 - Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men

AU - Taylor, Stephen

AU - Reynolds, H

AU - Sabin, CA

AU - Drake, Susan

AU - White, David

AU - Back, DJ

AU - Pillay, Deenan

PY - 2001/10/1

Y1 - 2001/10/1

N2 - Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor, licensed for the treatment of HIV-1. Data on sanctuary site penetration are limited. Therefore, we measured efavirenz concentrations in the blood and semen of 19 HIV-1-positive men and found concentrations in seminal plasma averaged 10% of those in blood plasma. Furthermore, seminal plasma viral loads were suppressed by 24 weeks of therapy in all patients. These data suggest that efavirenz-containing regimens have antiviral activity within the male genital tract.

AB - Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor, licensed for the treatment of HIV-1. Data on sanctuary site penetration are limited. Therefore, we measured efavirenz concentrations in the blood and semen of 19 HIV-1-positive men and found concentrations in seminal plasma averaged 10% of those in blood plasma. Furthermore, seminal plasma viral loads were suppressed by 24 weeks of therapy in all patients. These data suggest that efavirenz-containing regimens have antiviral activity within the male genital tract.

M3 - Article

C2 - 11600838

VL - 15

SP - 2051

EP - 2053

JO - Aids

JF - Aids

IS - 15

ER -

Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men

Abstract

UN SDGs

Fingerprint

Cite this